FDA Accepts Telix's NDA for Glioma Imaging Agent TLX101-Px, Sets September 2026 Review Deadline
Event summary
- FDA accepted Telix's resubmitted NDA for TLX101-Px (Pixclara®), a PET imaging agent for glioma characterization, with a PDUFA goal date of September 11, 2026.
- TLX101-Px has received Orphan Drug and Fast Track designations from the FDA, addressing a critical unmet need in distinguishing tumor progression from treatment-related changes in glioma patients.
- The imaging agent targets L-type amino acid transporters (LAT1 and LAT2), potentially serving as a patient selection and response assessment tool for Telix's therapy candidate TLX101-Tx.
- Telix's FY 2026 financial guidance does not include any revenue contribution from TLX101-Px.
The big picture
The FDA's acceptance of Telix's NDA for TLX101-Px marks a significant step in addressing the critical need for improved glioma imaging, a market with approximately 24,000 new cases diagnosed annually in the U.S. The Fast Track and Orphan Drug designations underscore the strategic importance of this imaging agent in differentiating tumor progression from treatment-related changes, a challenge that remains one of the most difficult aspects of glioma care. Telix's ability to leverage this approval could enhance its position in the radiopharmaceuticals sector, particularly in oncology.
What we're watching
- Regulatory Approval
- Whether the FDA will approve TLX101-Px by the September 2026 PDUFA deadline, enabling Telix to address the significant unmet need in glioma imaging.
- Commercialization Strategy
- How Telix plans to integrate TLX101-Px into its portfolio and the potential impact on its financial performance, given the absence of revenue contribution in FY 2026 guidance.
- Therapeutic Synergy
- The pace at which TLX101-Px can be utilized as a companion diagnostic for TLX101-Tx, Telix's LAT1-targeting therapy candidate currently in the IPAX-BrIGHT trial.
Related topics